Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Faiza Rharbaoui

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2019
Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple MyelomaSundar Jagannath, Leonard T Heffner, Sikander Ailawadhi, et al.
Annals of the Rheumatic Diseases|January 19, 2018
Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trialRonald F van Vollenhoven, Edward Clark Keystone, Vibeke Strand, et al.
Nature Chemical Biology|May 1, 2012
A selective inhibitor reveals PI3Kγ dependence of T(H)17 cell differentiationGiovanna Bergamini, Kathryn Bell, Satoko Shimamura, et al.
The Lancet. Haematology|September 16, 2021
Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a studyKevin R Kelly, Sikander Ailawadhi, David S Siegel, et al.
Cell Metabolism|December 21, 2021
Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonistMartin Bossart, Michael Wagner, Ralf Elvert, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2019
Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple MyelomaSundar Jagannath, Leonard T Heffner, Sikander Ailawadhi, et al.
Annals of the Rheumatic Diseases|January 19, 2018
Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trialRonald F van Vollenhoven, Edward Clark Keystone, Vibeke Strand, et al.
Nature Chemical Biology|May 1, 2012
A selective inhibitor reveals PI3Kγ dependence of T(H)17 cell differentiationGiovanna Bergamini, Kathryn Bell, Satoko Shimamura, et al.
The Lancet. Haematology|September 16, 2021
Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a studyKevin R Kelly, Sikander Ailawadhi, David S Siegel, et al.
Cell Metabolism|December 21, 2021
Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonistMartin Bossart, Michael Wagner, Ralf Elvert, et al.
Pageof 2